UK Expert Warns Unregulated Peptide Sales Create ‘Wild West’ Risk
Sunday, July 12th, 2026 - A leading UK endocrinologist warned that Britain is becoming a “wild west” for experimental peptides sold online without regulatory oversight, with growing sales of unapproved injectable drugs creating a risk of serious harm or fatalities. Prof. Channa Jayasena of Imperial College London told The Guardian that responsibility for policing the market falls between multiple regulators, leaving consumers exposed to products with unknown safety profiles.
Regulation leads the story
Prof. Jayasena said the online peptide market has expanded rapidly, with products marketed for muscle growth, fat loss, skin tanning, and anti-aging sold directly to consumers without prescriptions or medical supervision. He noted that some of these compounds are experimental drugs never tested in humans, while others are unlicensed versions of prescription medicines. The professor called for urgent regulatory action, saying the current situation leaves patients “playing Russian roulette with their health.”
The Medicines and Healthcare products Regulatory Agency (MHRA) has enforcement powers over unlicensed medicines sold in the UK, but Prof. Jayasena said the agency lacks resources to monitor the growing number of online vendors. He added that responsibility is fragmented between the MHRA, trading standards, and local authorities, creating gaps that sellers exploit.
Fitness influencers linked to Telegram steroid market
Separate reporting by The Guardian found that ambassadors for a wellness brand called Gencore Global directed followers to Telegram channels promoting steroids, prescription medicines, and experimental peptides. The investigation linked fitness influencers to an illegal steroid market operating on the encrypted messaging platform, with peptide products among the substances advertised.
‘Barbie peptide’ resurfaces in online sales
Yahoo Health reported renewed interest in melanotan, a synthetic peptide injection marketed as the “Barbie peptide” for its skin-darkening effects. The compound mimics a hormone that stimulates melanin production but is not approved for cosmetic use by any major regulator. Health authorities have previously warned that unregulated melanotan injections carry risks including skin cancer, moles changes, and cardiovascular effects.
Compounding pharmacies face a narrower path
The FDA has determined that the shortage of tirzepatide injection, a dual GIP/GLP-1 drug, has been resolved, ending the ability for compounding pharmacies to produce bulk copies under federal shortage exemptions. The decision narrows the legal pathway for compounded versions of the drug, which had been widely prescribed through telehealth platforms for weight management.
Pipeline records keep retatrutide in focus
Researchers continue to advance peptide drug development through novel methods. Engineers at multiple institutions have developed AI tools to design peptides that can turn cellular signals on or off, according to Medical Xpress. Separately, a study published in Nature’s Scientific Reports described computational discovery of a plant-derived defensin-like peptide targeting cancer-related receptors.
Sports rules remain separate
Athletes using peptide products should verify current World Anti-Doping Agency rules, which prohibit peptide hormones, growth factors, and related substances. The WADA prohibited list is updated annually and includes specific restrictions on compounds that may be sold through unregulated online channels.
Related reading: /tracker/ | /regulatory/fda-warning-letters-tracker/ | /regulatory/503a-vs-503b-compounding-explained/
